Amgen Planning Pivotal Obesity Program For MariTide

MariTide Phase III Trials To Include Diabetes

 
• By Mandy Jackson

Executives said during Amgen’s Q1 call that the company is “encouraged” by interim Phase II data for MariTide (AMG 133) in obesity, so it is designing Phase III trials and building manufacturing capacity. 

Professional nutritionist sitting at desk and writing a meal plan, measuring tape and apple
Phase III trials are planned in obesity, related conditions and diabetes • Source: Shutterstock

More from Alimentary/Metabolic

More from Therapy Areas